Interferon-gamma in the first-line therapy of ovarian cancer: A randomized phase III trial

British Journal of Cancer

Volumn 82, Issue 6, 2000, Pages 1138-1144

  Windbichler, G H ^a   Hausmaninger, H ^b   Stummvoll, W ^c   Graf, A H ^b   Kainz, C ^d   Lahodny, J ^b   Denison, U ^e   Muller Holzner E ^a   Marth, C ^a  

^a UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

^b GENERAL HOSPITAL   (Austria)

^c Krankenhaus der Barmherzigen Schwestern Wien Betriebsgesellschaft   (Austria)

^d UNIVERSITY OF VIENNA   (Austria)

^e WILHELMINEN HOSPITAL   (Austria)

Author keywords

Interferon type II; Multicentre study; Ovarian cancer; Randomized phase III trial

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; RECOMBINANT GAMMA INTERFERON;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CHILL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FATIGUE; FEVER; FLU LIKE SYNDROME; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MYALGIA; NEUROTOXICITY; NEUTROPENIA; OTOTOXICITY; OVARY CANCER; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; THROMBOSIS; VIRUS INFECTION; VOMITING;

EID: 0034010642     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1054/bjoc.1999.1053     Document Type: Article

References (25)

1. Allavena P, Peccatori F, Maggioni D, Erroi A, Sironi M, Colombo N, Lissoni A, Galazka A, Meiers W, Mangioni C and Mantovani A (1990) Intraperitoneal recombinant γ-interferon in patients with recurrent ascitic ovarian carcinoma: modulation of cytotoxicity and cytokine production in tumor-associated effectors and of major histocompatibility antigen expression on tumor cells. Cancer Res 50: 7318-7323
2. Aulitzky W, Gastl G, Aulitzky WE, Nachbaur K, Lanske B, Kemmler G, Flener R, Frick J and Huber C (1987) Interferon-γ for the treatment of metastatic renal cancer: dose-dependent stimulation and downregulation of beta-2 microglobulin and neopterin responses. Immunobiology 176: 85-95
3. Berek JS, Hacker NF, Lichtenstein A, Jung T, Spina C, Knox RM, Brady J, Greene T, Ettinger LM, Lagasse LD, Bonnem EM, Spiegel RJ and Zighelboim J (1985) Intraperitoneal recombinant α-interferon for 'salvage' immunotherapy in stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. Cancer Res 45: 4447-4453
4. Billiau A (1996) Interferon-γ: biology and role in pathogenesis. Adv Immunol 62: 61-130
5. Boehm U, Klamp T, Groot M and Howard JC (1997) Cellular responses to interferon-γ. Annu Rev Immunol 15: 749-795
6. Colombo N, Peccatori F, Paganin C, Bini S, Brandley M, Mangioni C, Mantovani A and Allavena P (1992) Anti-tumor and immunomodulatory activity of intraperitoneal IFN-gamma in ovarian carcinoma patients with minimal residual tumor after chemotherapy. Int J Cancer 51: 42-46
7. D'Acquisto R, Markman M, Hakes T, Rubin S, Hoskins W and Lewis JL (1988) A phase I trial of intraperitoneal recombinant gamma-interferon in advanced ovarian carcinoma. J Clin Oncol 6: 689-695
8. Dighe AS, Richards E, Old LJ and Schreiber RD (1994) Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN-γ receptors. Immunity 1: 447-456
9. Hancock MC, Langton BC, Chan T, Toy P, Monahan JJ, Mischak RP and Shawver LK (1991) A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diaminedichloroplatinum against human breast and ovarian tumor cell lines. Cancer Res 51: 4575-4580
10. Kaplan DH, Shankaran V, Dighe AS, Stockert E, Aguet M, Old LJ and Schreiber RD (1998) Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci USA 95: 7556-7561
11. Kleinerman ES, Kurzrock R, Wyatt D, Quesada JR, Gutterman JU and Fidler IJ (1986) Activation or suppression of the tumoricidal properties of monocytes from cancer patients following treatment with recombinant γ-interferon. Cancer Res 46: 5401-5405
12. Malik STA, Knowles RG, East N, Lando D, Stamp G and Balkwill FR (1991) Antitumor activity of γ-interferon in ascitic and solid tumor models of human ovarian cancer. Cancer Res 51: 6643-6649
13. Maluish AE, Urba WJ, Longo DL, Overton WR, Coggin D, Crisp ER, Williams R, Sherwin SA, Gordon K and Steis RG (1988) The determination of an immunologically active dose of interferon-gamma in patients with melanoma. J Clin Oncol 6: 434-445
14. Mannel DN and Falk W (1983) Interferon-gamma is required in activation of macrophages for tumor cytotoxicity. Cell Immunol 79: 396-402
15. Marth C, Fuith LC, Böck G, Daxenbichler G and Dapunt O (1989) Modulation of ovarian carcinoma tumor marker CA-125 by γ-interferon. Cancer Res 49: 6538-6542
16. Marth C, Müller-Holzner E, Greiter E, Cronauer MV, Zeimet AG, Doppier W, Eibl B, Hynes NE and Daxenbichler G (1990) γ-interferon reduces expression of the protooncogen c-erbB-2 in human ovarian carcinoma cells. Cancer Res 50: 7037-7041
17. Marth C, Zeimet AG, Herold M, Brumm C, Windbichler G, Müller-Holzner E, Offner F, Feichtinger H, Zwierzina H and Daxenbichler G (1996) Different effects of interferons, interleukin-1β and tumor necrosis factor-α in normal (OSE) and malignant human ovarian epithelial cells. Int J Cancer 67: 826-830
18. Marth C, Widschwendter M, Kærn J, Jørrgensen N-P, Windbichler G, Zeimet AG, Tropé C and Daxenbichler G (1997) Cisplatin resistance is associated with reduced interferon-γ-sensitivity and increased HER-2 expression in cultured ovarian cancer cells. Br J Cancer 76: 1328-1332
19. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL and Davidson M (1996) Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334:1-6
20. Nehmé A, Julia AM, Jozan S, Chevreau C, Bugat R and Canal P (1994) Modulation of cisplatin cytotoxicity by human recombinant interfcron-gamma in human ovarian cancer cell lines. Eur J Cancer 30A: 550-525
21. Ozols RF, Rubin SC, Thomas G and Robboy S (1997) Epithelial ovarian cancer. In: Principles and Practice of Gynecologic Oncology, 2nd edn, Hoskins WJ, Perez CA and Young RC (eds), pp. 919-986. Lippincott-Raven: Philadelphia
22. Pujade-Lauraine E, Guastalla JP, Colombo N, Devillier P, François E, Fumoleau P, Monnier A, Nooy M, Mignot L, Bugat R, Marques C, Mousseau M, Netter G, Maloisel F, Larbaoui S and Brandely M (1996) Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second look laparotomy. J Clin Oncol 14:343-350
23. Saito T, Berens ME and Welander CE (1986) Direct and indirect effects of human recombinant gamma-interferon on tumor cells in a clonogenic assay. Cancer Res 46: 1142-1147
24. Weisenthal LM, Dill PL and Pearson FC (1991) Effect of prior cancer chemotherapy on human tumor-specific cytotoxicity in vitro in response to immunopotentiating biologic response modifiers. J Natl Cancer Inst 83: 37-42
25. Welander CE, Homesley HD, Reich SD and Levin EA (1988) A phase II study of the efficacy of recombinant interferon gamma in relapsing ovarian adenocarcinoma. Am J Clin Oncol 11: 465-469